ARTICLE
Direct Contracting — a Pathway Forward for Healthcare Delivery Amidst COVID-19
December 10, 2020
Read time: 1 min
ARTICLE
December 10, 2020
Read time: 1 min
ARTICLE
December 10, 2020
Read time: 1 min

ARTICLE
Dec 10, 2020
Read time: 6 min
The US Court of Appeals for the Seventh Circuit amended its August 2020 opinion in Epic Systems v. Tata Consultancy to clarify that its analysis of punitive damages applies only to this particular case. Epic Systems Corp. v. Tata Consultancy Services Ltd., Case Nos. 19-1528, -1613 (7th Cir. Nov. 19, 2020) (Kanne, J.)
In the district court action, the jury found that Tata Consultancy Services Ltd. (TCS) used fraudulent means to access and steal Epic System’s trade secrets and other confidential information, and awarded $240 million in compensatory damages and $700 million in punitive damages. The district court reduced the compensatory damage award to $140 million and reduced the punitive damages award to $280 million based on a Wisconsin statutory cap on punitive damages. Both sides appealed.
On appeal, TCS contested the award of $280 million in punitive damages for various reasons, including that the award was not in line with the due process clause of the 14th Amendment. In its amended opinion, the Seventh Circuit clarified that “the Constitution is not the most relevant limit to a federal court when assessing punitive damages, as it comes into play only after the assessment has been tested against statutory and common law principles. . . . Indeed, a federal court can and should reduce a punitive damages award sometime before it reaches the outermost limits of due process.”
The Seventh Circuit analyzed the three “guideposts” for determining whether there is a due process violation with respect to punitive damages awards:
The Court’s analysis of the first guidepost remained relatively unchanged from its original opinion, in which the Court found that a punitive damages award was justified.
The Seventh Circuit deviated from its original opinion in its analysis of the second and third guideposts. The Court found that determining the harm in the second guidepost was somewhat more difficult, because the $140 million compensatory award was based on benefit to TCS, not harm to Epic. However, the Court noted that in such instances, “few awards exceeding a single-digit ratio between punitive damages and compensatory damages will satisfy due process.” In its original opinion, the Court concluded that “a 2:1 ratio exceeds the outermost limit of the due process guarantee.” As amended, however, the Court softened this language and clarified that the 2:1 ratio exceeds only the outermost limit “in this case.” The Court explained that although TCS’s conduct was reprehensible, it was not egregious. The Court similarly concluded that the third guidepost warranted a 1:1 ratio of punitive to compensatory damages. Here again, while the Court’s original opinion applied to the “federal constitution,” the amended opinion reduced the scope of the holding to “this case” only.
Practice Note: While the Seventh Circuit originally seemed to indicate that any punitive damages award that exceeds a compensatory award by a ratio of 2:1 violates due process, the Court’s amendments seem to leave open the possibility that such a punitive award may still be issued in cases of “egregious” misconduct on the part of the defendant.

ARTICLE
December 9, 2020
Read time: 1 min

ARTICLE
December 9, 2020
Read time: 1 min
ARTICLE
December 9, 2020
Read time: 2 min
The employer has a right to the work products of its employees. While the employer will automatically become the owner of all physical objects produced, the rights to intellectual property such as inventions or copyrighted works will initially be owned by employees. The employer then needs a specific legal basis in each case to transfer the rights accrued by the employees to itself: a basis for this may be provisions of the Employee Invention Act, the Copyright Act or stipulations in labor contracts.
Dr. Henrik Holzapfel gives an overview of this in the chapter “Recht am Arbeitsergebnis” (right to the work product) of the “Tschöpe” handbook on labor law.

ARTICLE / CLIENT ALERT
December 9, 2020
Read time: 3 min
On Nov. 30, 2020, Intercontinental Exchange Inc. announced[1] that ICE Benchmark Administration Limited (“IBA”), the administrator of London Interbank Offered Rates (“LIBOR”), will consult on its intention to cease publication of U.S. dollar-denominated London Interbank Offered Rates (“USD LIBOR”):
IBA noted that any publication beyond Dec. 31, 2021 of the overnight, one-month, three-month, six-month and twelve-month USD LIBOR rates will need to comply with applicable regulations, including as to representativeness. The June 30, 2023 final publication date represents what would be an extension for such tenors beyond the previously announced Dec. 31, 2021 final publication date.
Also on Nov. 30, 2020, the Alternative Reference Rates Committee (“ARRC”) issued a press release[2] in which it “applauded concurrent announcements” by IBA as well as its regulator, and U.S. regulators, in regards to the proposed path forward in transitioning away from USD LIBOR, including supervisory guidance encouraging banks to stop new LIBOR issuances by the end of 2021, and IBA’s plan to consult on specific timing for ceasing the publication of LIBOR. According to the ARRC’s press release, these developments together support a smooth transition for legacy contracts by allowing time for most to mature before USD LIBOR is proposed to cease, subject to consultation outcomes. In the ARRC’s press release the ARRC noted that these developments align with the ARRC’s efforts, and will accelerate the use by market participants of the Secured Overnight Financing Rate (“SOFR”), the ARRC’s preferred alternative to USD LIBOR.
Authored by Phillip J. Azzollini, Taleah E. Jennings, Douglas I. Koff, Craig Stein and Atul Joshi.
If you have any questions concerning this Alert or would like assistance with the transition from LIBOR, please contact your attorney at Schulte Roth & Zabel or one of the authors.
For the latest information on preparing for the transition from LIBOR, visit SRZ’s LIBOR Transition Resource Center.
[1] View the IBA announcement.
[2] View the ARRC press release.
This communication is issued by Schulte Roth & Zabel LLP for informational purposes only and does not constitute legal advice or establish an attorney-client relationship. In some jurisdictions, this publication may be considered attorney advertising. ©2020 Schulte Roth & Zabel LLP.
All rights reserved. SCHULTE ROTH & ZABEL is the registered trademark of Schulte Roth & Zabel LLP.

ARTICLE / CLIENT ALERT
December 8, 2020
Read time: 8 min
In a fourth amendment to the March 17, 2020, Public Readiness and Emergency Preparedness Act (PREP Act), the US Department of Health and Human Services (HHS) has expanded access to COVID-19 Covered Countermeasures through telehealth and clarified the scope of liability protections provided by the PREP Act. In particular, the declaration is important to telehealth providers because it appears to preempt, under certain circumstances, state laws that have limited cross-border practice of medicine using telehealth. Healthcare providers should take note that the licensure exception and any immunity protections are limited to healthcare providers who are ordering or administering a Covered Countermeasure and there is no indication of intent to expand beyond these focused measures.
Late last week, the US Department of Health and Human Services (HHS) announced a fourth amendment to the Public Readiness and Emergency Preparedness Act (PREP Act) declaration dated March 17, 2020, which is intended to expand access to COVID-19 Covered Countermeasures through telehealth and clarify the scope of liability protections provided by the PREP Act. According to HHS, the amendment authorizes telehealth providers to order or administer Covered Countermeasures (defined below) for patients who are located in other states and it extends liability protections under the PREP Act to covered persons for recommended activities related to any Covered Countermeasures authorized or approved by the Food and Drug Administration (FDA) for COVID-19 and to any respiratory protective device approved by the National Institute for Occupational Safety and Health for use during the public health emergency (PHE).
What is the PREP Act?
The PREP Act, which was enacted in 2005, provides the HHS Secretary with the authority to make declarations that provide immunity from liability under certain circumstances, including “claims of loss caused, arising out of, relating to, or resulting from administration or use of countermeasures to diseases, threats and conditions; determined by the secretary to constitute a present, or credible risk of a future public health emergency; and to entities and individuals involved in the development, manufacture, testing, distribution, administration, and use of such countermeasures.” The initial PREP Act declaration related to the current PHE was issued in mid-March 2020 and there have been three other amendments to the declaration before this latest one.
Note that a PREP Act declaration and a PHE declaration are different—they are made based on different public health determinations and have different legal effects. For example, the PREP Act declaration may be made before a PHE declaration and its liability protections can apply to activities that precede and follow the PHE declaration.
Why is this latest amendment to the declaration particularly relevant to telehealth providers?
This latest declaration has captured the attention of telehealth providers because it appears to preempt, under certain circumstances, state laws that have limited cross-border practice of medicine using telehealth. Specifically, Section V.e of the amended declaration now provides that “[w]hen ordering and administering Covered Countermeasures by means of telehealth to patients in a state where the healthcare personnel are not already permitted to practice, the healthcare personnel must comply with all requirements for ordering and administering Covered Countermeasures to patients by means of telehealth in the state where the healthcare personnel are permitted to practice. Any state law that prohibits or effectively prohibits such a qualified person from ordering and administering Covered Countermeasures by means of telehealth is preempted. Nothing in this Declaration shall preempt state laws that permit additional persons to deliver telehealth services.”
In its description of the amendment, the Secretary notes that “[t]elehealth is widely recognized as a valuable tool to promote public health during this pandemic,” and references assessments of the utility of telehealth services by the Centers for Disease Control and Prevention and support for the utilization of telehealth services by HSS and its component agencies and offices, including the Centers for Medicare and Medicaid Services and the Office for Civil Rights.
What is a “Covered Countermeasure”?
Under the March 10, 2020, HHS PREP Act declaration, a Covered Countermeasure is a product such as a drug, diagnostic, device or vaccine that is used to diagnose, mitigate, prevent, treat, or cure COVID-19 or the transmission of SARS-CoV-2 (or a virus mutated from SARS-CoV-2) or any serious or life-threatening disease or condition caused by the use of a Covered Countermeasure. A Covered Countermeasure could also be a product or technology intended to enhance another Covered Countermeasure or a device used in the administration of another Covered Countermeasure. In order to qualify as a Covered Countermeasure, the product or technology must be appropriately cleared or approved by the FDA or authorized for emergency use in accordance with the Federal Food, Drug and Cosmetic Act.
In the telehealth context, Covered Countermeasures such as diagnostic tests or vaccines may be ordered by telehealth providers after a virtual encounter with a patient and filled or administered by the patient’s pharmacy or laboratory.
What is the implication on state licensing laws and why does this matter? What about other telehealth rules?
Any state laws that prohibit a qualified person from ordering or administering a Covered Countermeasure through telehealth is preempted, including licensing laws.
State licensure has been extremely burdensome for telehealth providers. Generally, a provider must be licensed in the state in which a patient is located at the time of the telehealth visit, unless a licensure exception applies. While many states waived licensure requirements or implemented streamlined registration processes in response to COVID-19, the waivers in many states are expiring or have expired, or were narrowly drafted resulting in limited utility. In sum, each state has different professional licensure rules, which can make multistate telehealth programs challenging to implement. While this amendment is a very narrow exception to licensure requirements because it is limited to Covered Countermeasures, it will likely assist in the implementation of multistate testing and vaccination programs. Telehealth providers will still need to comply with applicable state rules (provided that these rules do not prohibit or effectively prohibit the ordering or administering Covered Measures). In addition, acts that constitute “willful misconduct” are not protected from the PREP Act. Healthcare providers still must provide care that meets the applicable standard of care.
Is the statement of preemption found in this latest declaration effective?
The Office of the General Counsel (OGC) of HHS would likely advise that it is effective for preempting state licensure rules for telehealth providers engaged in Covered Countermeasures. HHS Advisory Opinion 20-02 sets forth the argument for preemption under the PREP Act with respect to pharmacists being able to administer COVID-19 tests independent of state licensing laws. The reasoning set forth in this opinion applies to the cross-border practice by physicians as well. As noted in the opinion, pharmacists, pharmacies and one trade association asked the OGC whether the PREP Act preempts state licensing laws that restrict the ability of pharmacists to order and administer COVID-19 diagnostic tests where HHS has expressly authorized pharmacists, under the PREP Act, to order and administer those tests. The opinion concludes that the PREP Act, in conjunction with the Secretary’s March 10, 2020, PREP Act declaration, preempts any state or local requirement that prohibits or effectively prohibits a pharmacist from ordering and administering a COVID-19 diagnostic test that the FDA has authorized, which could include state licensure rules.
What are the key takeaways?
The licensure exception and any immunity protections are limited to healthcare providers who are ordering or administering a “Covered Countermeasure,” and there is no indication that it is intended to expand beyond these focused measures. Even if a provider can leverage this licensure exception to support the delivery of Covered Countermeasures, telehealth providers must still comply with applicable state telehealth laws that are not covered under this amendment (i.e., those that do not prohibit or effectively prohibit the ordering or administering of Covered Countermeasures).

ARTICLE / REPORT / US POLICY
December 8, 2020
Read time: 2 min
Drug prices have emerged as an important US political issue in recent years, with roughly 140 bills on drug prices introduced in the US Congress since January 2019. On November 20, 2020, the US Department of Health and Human Services (HHS) announced an interim final rule with comment that will introduce sweeping changes to the way many drugs are reimbursed by Medicare Part B in the United States by adopting a system of external reference pricing (ERP) using a “most-favored nation” (MFN) pricing approach. With a change in administration on January 20, 2021, and potential legal challenges on the horizon, it is uncertain whether this rule will be implemented as published. There is bipartisan interest in drug pricing legislation with an ERP approach having support across the political aisle. This suggests that even if the MFN interim final rule is not implemented as published, an ERP approach may likely be a part of future policymaking on ratesetting for drugs under Medicare.
ARTICLE
December 8, 2020
Read time: 1 min